HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
Phase 3
Completed
- Conditions
- Infection, Human Immunodeficiency Virus IHIV-1 Infection
- Interventions
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 212
- Registration Number
- NCT00450580
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients
Phase 4
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: GI265235
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 974
- Registration Number
- NCT00441688
Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection
Phase 3
Completed
- Conditions
- Infection, Human Immunodeficiency Virus IHIV Infection
- Interventions
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2012-03-22
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 515
- Registration Number
- NCT00440947
- Locations
- 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico
Expanded Access Program for Maraviroc At Multiple Centers
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 1047
- Registration Number
- NCT00426660
- Locations
- 🇺🇸
AltaMed Health Services Corporation, Los Angeles, California, United States
🇺🇸Synergy Hematology-Oncology Associates, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone
Phase 4
Completed
- Conditions
- CHRONIC HEPATITIS B
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 100
- Registration Number
- NCT00354653
- Locations
- 🇮🇷
GSK Clinical Trials Call Center, Tehran, Iran, Islamic Republic of
A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects
Phase 3
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 753
- Registration Number
- NCT00296504
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults
Phase 2
Completed
- Conditions
- Infection, Human Immunodeficiency Virus IHIV Infection
- First Posted Date
- 2005-11-23
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 30
- Registration Number
- NCT00257621
- Locations
- 🇺🇸
GSK Investigational Site, Seattle, Washington, United States
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase 2
Terminated
- Conditions
- Infection, Human Immunodeficiency Virus IHIV-1 Infection
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 130
- Registration Number
- NCT00242879
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
Phase 3
Completed
- Conditions
- HIV InfectionInfection, Human Immunodeficiency Virus I
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 20
- Registration Number
- NCT00242840
- Locations
- 🇮🇹
GSK Investigational Site, Brescia, Lombardia, Italy
Fosamprenavir Expanded Access
Phase 4
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2016-09-12
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 85
- Registration Number
- NCT00240552
- Locations
- 🇨🇭
GSK Investigational Site, Zurich, Switzerland
© Copyright 2025. All Rights Reserved by MedPath